HomeCONGRESS

CONGRESS

ESC 2024 | QUADRO Trial: Efficacy and Safety of the First Quadruple Therapy Single Pill in Resistant Hypertension Patients

Researchers conducted an international, randomized, parallel-group study with a superiority design over a 16-week period. The doses...

ESC 2024 | STOP-or-NOT Trial: Optimal Management of Renin-Angiotensin System Inhibition Before Non-Cardiac Surgery

Researchers conducted a multicenter, randomized study to assess the continuation of renin-angiotensin system inhibition (RASI) before major...

ESC 2024 | AßYSS: Discontinuation of Beta-Blocker Treatment After One Year in Uncomplicated MI

Researchers presented a non-inferiority study conducted at 49 centers in France, with a randomized cohort of stable post-acute...

SOLACI-CACI 2024 – Presentations day 3

Discover the highlights of the third day of activities of  SOLACI-CACI 2024 Congress, held from August 7 to 9 at...

SOLACI-CACI 2024 – Day 2 Presentations

Discover the highlights of the second day of activities of  SOLACI-CACI 2024 Congress, held from August 7 to 9 at...

SOLACI-CACI 2024 – Day 1 Presentations

Discover the highlights of the first day of activities of SOLACI-CACI 2024 Congress, held from August 7 to 9...

14th Edition of ProEducar Fellows Course Held at SOLACI-CACI 2024

With a new modality, the 14th edition of ProEducar Fellows Course was held during SOLACI-CACI 2024, which...

SOLACI Research Registries Continue to Grow

SOLACI Research department put us up to speed on their Research Registry progress during SOLACI-CACI 2024. Similarly,...